Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">ARX-02: Phase II started</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

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

AcelRx began a double-blind, placebo-controlled, crossover Phase II trial to evaluate sublingual ARX-02 in 42 patients. ......

cancer

Neurology

Ophthalmic

ARX-02: Phase II started

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Discovery & Translation Analysis

Discovery & Translation

Hot Topics

BioCentury Podcasts 

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data Coverage

BCIQ Data

All Events

Bio€quity Europe

Grand Rounds — U.S.

Grand Rounds — Europe

The BioCentury-BayHelix China Healthcare Summit

China Healthcare Summit

BioCentury-BayHelix East-West Summit 2027

East-West Biopharma Summit

Podcast: The BioCentury Show

Podcast: BioCentury This Week

Webinars

Events

My Workspace

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Subscription

Sponsorship & Branding Inquiry

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Request a Trial

Contact

Home